| Literature DB >> 30379967 |
Jeanine M Van Ancum1, Nini H Jonkman1, Natasja M van Schoor2, Emily Tressel1, Carel G M Meskers1,3, Mirjam Pijnappels1, Andrea B Maier1,4.
Abstract
OBJECTIVES: The metabolic syndrome has been associated with a variety of individual variables, including demographics, lifestyle, clinical measures and physical performance. We aimed to identify independent predictors of the prevalence and incidence of metabolic syndrome in a large cohort of older adults.Entities:
Mesh:
Year: 2018 PMID: 30379967 PMCID: PMC6209297 DOI: 10.1371/journal.pone.0206424
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flowchart.
LASA: Longitudinal Aging Study Amsterdam, MetS: Metabolic Syndrome.
Characteristics of the cross-sectional cohort and the longitudinal sub-cohort.
| Variables | Cross-sectional cohort (n = 1292) | Longitudinal sub-cohort (n = 218) | ||||||
|---|---|---|---|---|---|---|---|---|
| N | MetS prevalence | N | MetS incidence | |||||
| No (n = 813) | Yes (n = 479) | No (n = 152) | Yes (n = 66) | |||||
| Sex, female | 1292 | 384 (47.2) | 278 (58.0) | 218 | 66 (43.4) | 32 (48.5) | ||
| Age, years, mean (SD) | 1292 | 75.3 (6.5) | 75.7 (6.6) | 218 | 71.3 (6.5) | 71.2 (6.2) | ||
| Living status, living alone | 1292 | 308 (37.9) | 214 (44.7) | 218 | 38 (25.0) | 26 (39.4) | ||
| Education | 537 | 300 (37.0) | 237 (49.5) | 84 | 57 (37.5) | 27 (40.9) | ||
| 599 | 399 (49.2) | 200 (41.8) | 104 | 73 (48.0) | 31 (47.0) | |||
| 154 | 112 (13.8) | 42 (8.8) | 30 | 22 (14.5) | 8 (12.1) | |||
| Income | 285 | 159 (21.0) | 126 (29.1) | 59 | 41 (30.1) | 18 (30.0) | ||
| 286 | 175 (23.1) | 111 (25.6) | 37 | 22 (16.2) | 15 (25.0) | |||
| 342 | 219 (29.0) | 123 (28.4) | 50 | 35 (25.7) | 15 (25.0) | |||
| 276 | 203 (26.9) | 73 (16.9) | 50 | 38 (27.9) | 12 (20.0) | |||
| Retired | 1259 | 752 (94.7) | 448 (96.3) | 217 | 132 (86.8) | 61 (93.8) | ||
| Current smoking | 1292 | 160 (19.7) | 74 (15.4) | 218 | 28 (18.4) | 11 (16.7) | ||
| Alcohol, units/week, median (IQR) | 1291 | 4 (0−12) | 2 (0−7) | 217 | 3.0 (0−7) | 2 (0−7) | ||
| LAPAQ | 311 | 183 (23.3) | 128 (28.0) | 54 | 38 (25.2) | 16 (24.6) | ||
| 312 | 208 (26.5) | 104 (22.8) | 54 | 39 (25.8) | 15 (23.1) | |||
| 319 | 196 (24.9) | 123 (26.9) | 54 | 34 (22.5) | 20 (30.8) | |||
| 301 | 199 (25.3) | 102 (22.3) | 54 | 40 (26.5) | 14 (21.5) | |||
| MMSE, median (IQR) | 1289 | 28 (26−29) | 27 (26−29) | 218 | 28 (26−29) | 28 (27−29) | ||
| CES-D, median (IQR) | 1257 | 6 (3−12) | 6 (2−11) | 218 | 4 (1−10) | 5 (2−10) | ||
| Chronic diseases | 1291 | 126 (15.5) | 64 (13.4) | 218 | 19 (12.5) | 8 (12.1) | ||
| 1291 | 184 (22.7) | 158 (33.0) | 218 | 27 (17.8) | 14 (21.2) | |||
| 1291 | 65 (8.0) | 75 (15.7) | 218 | 11 (7.2) | 7 (10.6) | |||
| 1291 | 27 (3.3) | 76 (15.9) | 218 | 6 (3.9) | 5 (7.6) | |||
| 1291 | 42 (5.2) | 56 (11.7) | 218 | 5 (3.3) | 2 (3.0) | |||
| 1291 | 363 (44.7) | 237 (49.5) | 218 | 51 (33.6) | 25 (37.9) | |||
| 1291 | 89 (11.0) | 61 (12.7) | 218 | 13 (8.6) | 5 (7.6) | |||
| Polypharmacy | 1292 | 98 (12.1) | 115 (24.0) | 212 | 5 (3.4) | 6 (9.2) | ||
| BMI, kg/m2, mean (SD) | 1282 | 25.6 (3.9) | 29.0 (3.9) | 218 | 25.2 (3.3) | 27.3 (3.9) | ||
| Cardigan test, sec, mean (SD) | 1263 | 13.1 (6.2) | 14.2 (7.0) | 215 | 12.0 (5.4) | 12.3 (5.6) | ||
| 5-times STS test, sec, mean (SD) | 1143 | 13.1 (5.0) | 13.9 (5.4) | 213 | 11.9 (3.8) | 12.7 (5.7) | ||
| Gait speed, meter/sec, mean (SD) | 1234 | 0.8 (0.3) | 0.8 (0.3) | 216 | 1.0 (0.4) | 0.9 (0.3) | ||
| BP, mmHg, mean (SD) | 1271 | 149.9 (24.9) | 159.4 (26.1) | 218 | 120.6 (22.8) | 125.4 (17.7) | ||
| 1271 | 82.1 (12.6) | 85.7 (14.7) | 218 | 66.6 (14.1) | 67.0 (16.2) | |||
| WC, cm, mean (SD) | 614 | 96.0 (9.5) | 105.2 (8.4) | 120 | 95.5 (8.2) | 101.7 (9.4) | ||
| 627 | 88.0 (10.7) | 98.3 (9.6) | 98 | 94.1 (11.0) | 99.7 (12.7) | |||
| Triglycerides, mmol/L, mean (SD) | 1291 | 1.2 (0.5) | 2.1 (0.9) | 218 | 1.8 (0.8) | 2.1 (1.1) | ||
| HDL, mmol/L, mean (SD) | 628 | 1.4 (0.4) | 1.0 (0.2) | 120 | 1.3 (0.3) | 1.1 (0.3) | ||
| 659 | 1.6 (0.4) | 1.1 (0.3) | 98 | 1.5 (0.3) | 1.4 (0.3) | |||
| LDL, mmol/L, mean (SD) | 627 | 3.4 (0.9) | 3.7 (1.0) | 120 | 3.7 (1.0) | 3.8 (0.9) | ||
| 652 | 3.7 (0.8) | 4.0 (1.1) | 98 | 4.0 (1.0) | 4.3 (1.4) | |||
| Fructosamine, μmol/L, mean (SD) | 1289 | 227.8 (29.9) | 248.5 (45.6) | − | − | |||
All variables are presented as n (%) unless indicated otherwise. BMI: Body Mass Index, BP: Blood Pressure, CES-D: Centre for Epidemiologic Studies-Depression Scale, CVA: Cerebrovascular Accident, HDL: High-Density Lipoprotein cholesterol, IQR: Interquartile Range, LAPAQ: LASA Physical Activity Questionnaire, MetS: Metabolic Syndrome, MMSE: Mini–Mental State Examination, N: Number of participants, OA: Osteoarthritis, RA: Rheumatoid Arthritis, SD: Standard Deviation, STS: Sit-To-Stand, WC: Waist circumference.
a MetS prevalence: baseline values T1 (1995).
b MetS incidence: baseline values T0 (1992–1995).
* Not reported as this variable was not measured in 1992.
Potential predictors of MetS prevalence in the cross-sectional cohort of community-dwelling older adults.
| Variables | Univariable | Multivariable | ||||||
|---|---|---|---|---|---|---|---|---|
| Odds Ratio | 95% CI | p-value | Odds Ratio | 95% CI | p-value | |||
| Sex, female | 1.55 | 1.23–1.94 | <0.001 | |||||
| Age, years | 1.01 | 0.99–1.03 | 0.21 | |||||
| Living status, living alone | 1.32 | 1.05–1.67 | 0.02 | |||||
| Education | 2.11 | 1.42–3.12 | <0.001 | |||||
| 1.34 | 0.90–1.98 | 0.15 | ||||||
| Income | 2.20 | 1.55–3.14 | <0.001 | |||||
| 1.76 | 1.23–2.52 | <0.01 | ||||||
| 1.56 | 1.10–2.21 | 0.01 | ||||||
| Retired | 1.47 | 0.83–2.62 | 0.19 | |||||
| Current smoking | 0.75 | 0.55–1.01 | 0.06 | |||||
| Alcohol, units/week | 0.98 | 0.97–0.99 | 0.001 | |||||
| LAPAQ, quartiles | 1.37 | 0.98–1.90 | 0.06 | |||||
| 0.98 | 0.70–1.36 | 0.89 | ||||||
| 1.22 | 0.88–1.70 | 0.23 | ||||||
| MMSE | 0.95 | 0.92–0.99 | 0.01 | |||||
| CES-D | 1.00 | 0.98–1.01 | 0.84 | |||||
| Chronic Diseases | 0.84 | 0.61–1.16 | 0.29 | |||||
| 1.68 | 1.31–2.16 | <0.001 | 1.91 | 1.37–2.65 | <0.001 | |||
| 2.13 | 1.50–3.04 | <0.001 | 2.13 | 1.32–3.42 | 0.002 | |||
| 5.48 | 3.48–8.64 | <0.001 | 4.74 | 2.65–8.48 | <0.001 | |||
| 2.43 | 1.60–3.68 | <0.001 | 1.92 | 1.09–3.37 | 0.024 | |||
| 1.21 | 0.97–1.52 | <0.001 | ||||||
| 1.19 | 0.84–1.68 | 0.34 | ||||||
| Polypharmacy | 2.31 | 1.71–3.10 | <0.001 | |||||
| BMI, kg/m2 | 1.26 | 1.22–1.31 | <0.001 | 1.32 | 1.26–1.38 | <0.001 | ||
| Cardigan test, sec | 1.03 | 1.01–1.04 | 0.01 | |||||
| 5-times STS test, sec | 1.03 | 1.01–1.06 | 0.01 | |||||
| Gait speed, meter/sec | 0.40 | 0.26–0.63 | <0.001 | |||||
95% CI: 95% confidence interval, BMI: Body Mass Index, CES-D: Centre for Epidemiologic Studies-Depression Scale, CVA: Cerebrovascular Accident, HDL: High-Density-Lipoprotein, IQR: Interquartile Range, LAPAQ: LASA Physical Activity Questionnaire, MetS: Metabolic Syndrome, MMSE: Mini–Mental State Examination, N: Number of participants, OA: Osteoarthritis, RA: Rheumatoid Arthritis, SD: Standard Deviation, STS: Sit-To-Stand.
Potential predictors of MetS incidence at three years follow-up in the longitudinal sub-cohort of community-dwelling older adults.
| Variables | Univariable | ||||
|---|---|---|---|---|---|
| Odds Ratio | 95% CI | p-value | |||
| Sex, female | 1.23 | 069–2.19 | 0.49 | ||
| Age, years | 1.00 | 0.95–1.04 | 0.91 | ||
| Living status, living alone | 1.95 | 1.05–3.61 | 0.03 | ||
| Education | 1.30 | 0.51–3.30 | 0.58 | ||
| 1.17 | 0.47–2.91 | 0.74 | |||
| Income | 1.39 | 0.59–3.26 | 0.45 | ||
| 2.16 | 0.86–5.43 | 0.10 | |||
| 1.36 | 0.56–3.30 | 0.50 | |||
| Retired | 2.31 | 0.76–7.05 | 0.14 | ||
| Current smoking | 0.89 | 0.41–1.91 | 0.76 | ||
| Alcohol, units/week | 0.99 | 0.95–1.03 | 0.56 | ||
| LAPAQ, quartiles | 1.20 | 0.52–2.80 | 0.67 | ||
| 1.10 | 0.47–2.58 | 0.83 | |||
| 1.68 | 0.74–3.82 | 0.22 | |||
| MMSE | 1.11 | 0.95–1.29 | 0.20 | ||
| CES-D | 1.01 | 0.97–1.05 | 0.75 | ||
| Chronic Diseases | 0.97 | 0.40–2.33 | 0.94 | ||
| 1.25 | 0.61–2.57 | 0.55 | |||
| 1.52 | 0.56–4.11 | 0.41 | |||
| 2.00 | 0.59–6.78 | 0.27 | |||
| 0.92 | 0.17–4.86 | 0.92 | |||
| 1.21 | 0.66–2.20 | 0.54 | |||
| 0.88 | 0.30–2.57 | 0.81 | |||
| Polypharmacy | 2.89 | 0.85–9.83 | 0.09 | ||
| BMI, kg/m2 | 1.19 | 1.09–1.30 | <0.001 | ||
| Cardigan test, sec | 1.01 | 0.96–1.07 | 0.70 | ||
| 5-times STS test, sec | 1.04 | 0.98–1.11 | 0.21 | ||
| Gait speed, meter/sec | 0.47 | 0.18–1.20 | 0.11 | ||
95% CI: 95% confidence interval, BMI: Body Mass Index, CES-D: Centre for Epidemiologic Studies-Depression Scale, CVA: Cerebrovascular Accident, HDL: High-Density-Lipoprotein, IQR: Interquartile Range, LAPAQ: LASA Physical Activity Questionnaire, MetS: Metabolic Syndrome, MMSE: Mini–Mental State Examination, N: Number of participants, OA: Osteoarthritis, RA: Rheumatoid Arthritis, SD: Standard Deviation, STS: Sit-To-Stand.
* BMI remains significant after multivariable analysis: Odds 1.16, 95% CI 1.05–1.27, p-value 0.002.